Why $350M Phase I Upfronts Don’t Mean Assets Are Suddenly “Worth More” –
Competition for unique, early-stage drugs has become so intense that the average upfront payment for a Phase I asset has risen to approximately $350 million. But don’t be fooled by the smaller upfront payments for later, Phase III assets. It’s not that they’re less valuable; it’s just that the deals are structured to keep options…